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Abstract
Background: Benzodiazepines are frequently prescribed to patients with drug use disorders. However, it has previously
been difficult to distinguish whether this frequent prescribing was due to underlying psychiatric disorders or
inappropriate prescribing. In a nationwide cohort study, we investigated the prescribing of benzodiazepines to
patients with drug use disorders in connection with treatment admission.
Methods: Benzodiazepine prescriptions to patients (N = 33203) aged 18 to 67 years admitting for outpatient
treatment for drug use disorders in Denmark, 2000 to 2010, were studied by using linked data from nationwide
health registries. Factors associated with increasing amounts of benzodiazepine use within the first year after admission
were assessed by multinomial logistic regression. Proportions of very long-term benzodiazepine prescription
were calculated.
Results: During the first year after admission to treatment, 26.2 % of patients were prescribed benzodiazepines.
Of these, 35.5 % were prescribed benzodiazepines at dose levels that might indicate inappropriate use (>365
Defined Daily Dose per year), and 34.6 % were prescribed more than one type of benzodiazepines. Diazepam was
the most commonly prescribed type. Among patients with opioid use, 43.2 % were prescribed benzodiazepines
which were three times higher than for patients with cannabis (12.2 %) or central stimulating drugs (13.8 %) as
their primary drug use. Admitting to treatment for a drug use disorder did not increase the specialized psychiatric
treatment coverage of this patient group, disregarding use of prescribed benzodiazepines. 29.5 % were new users
of prescribed benzodiazepines, and of these, 27.5 % continued into very long-term use (≥4 years after admission)
during the study period.
Conclusions: Benzodiazepines were commonly prescribed to patients admitting to treatment for drug use
disorders, and included prescription of multiple and non-optimal types, high doses, and very long-term prescriptions.
These findings point towards inappropriate prescribing of benzodiazepines in many cases more than treatment for
psychiatric disorders.
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Background
Drug use disorders (DUDs) are common medical condi-
tions and associated with significant morbidity and mor-
tality [1]. Treatment of DUD reduces illicit drug use,
morbidity, mortality, and crime [2–5]. In recent years,
outpatient treatment of DUD has largely replaced previ-
ous traditions of inpatient treatment [6].
Benzodiazepines (BZDs) have long been used for con-
ditions including various psychiatric disorders, insomnia,
acute alcohol withdrawal, and epilepsy [7]. However, the
use of BZDs has also been associated with a risk for de-
pendence, abuse, and overdose death [8]. Patients with
DUD use BZDs more frequently than the general popu-
lation, including both legally prescribed and illicitly ac-
quired BZDs [9]. Further, this patient group has both a
higher prevalence of psychiatric disorders and an in-
creased risk of developing a BZD abuse when using the
medication [10–13]. Therefore, it has previously been
difficult to distinguish whether the excess use of BZDs,
particularly legally prescribed BZDs, among patients with
DUD has been due to underlying psychiatric disorders or
abuse; two conditions which require entirely different
treatment regimes.
The prescribing of BZDs is mainly approved for short-
to intermediate-term treatment in low doses. Benzodiaz-
epines are not indicated for long-term use, except in the
case of severe generalized anxiety disorder [14, 15]. In
particular, long-term use among patients with DUD is of
increasing concern, as it can result in cognitive impair-
ment, difficulty in continuing treatment, tolerance, and
dependence and abuse of BZDs [16–18]. Furthermore,
the risk for adverse events, such as dependence and
abuse, differs among the different types of BZDs. Certain
types are preferred among drug using populations, and are
often used in combination with other drugs [17, 19, 20].
BZDs used in combination with opioids may be particu-
larly counterproductive in this patient group due to high
risk of abuse [21]. Therefore, long-term prescriptions, high
doses, less than optimal types of BZDs, and co-prescribing
of opioids are all likely indicators of inappropriate prescrib-
ing of BZDs. On the other hand, initiation of psychiatric
treatment for BZD users after admission to DUD treat-
ment would be a likely indicator of an underlying psychi-
atric disorder. Investigation of such indicators among
patients with DUD may help clarify whether the excess use
of BZDs among this patient group is due to an underlying
psychiatric disorders or inappropriate prescribing.
There are an estimated 33000 drug users in Denmark
(latest numbers from 2009) with relatively stable treat-
ment coverage of around 40 % during the last decades
[6]. The outpatient treatment for patients with DUD is
comprised of multiple service components, including
acute detoxification, medication-assisted treatment, case
management, and behavioral therapy. According to Danish
guidelines, BZDs should not be prescribed to patients with
DUD as a general rule [22]. Once admitted into treatment,
guidelines state that DUD treatment should address the
patient’s use of BZDs, and that BZDs should not be pre-
scribed without coordinating within the overall treatment
plan [22]. From 2000 to 2010, the prevalence of BZD use
in the general Danish population decreased considerably,
with an average one-year prevalence of 5-6 % during the
entire period [23–25].
The Danish national registries contain information on
patients seeking treatment for DUD, psychiatric disorders,
and dispensed prescription drugs. In this nationwide
study, we aimed to investigate the prescribing of BZDs in
a population admitted for treatment of DUD. For patients
with and without prior use of BZDs, we examined how
their primary drug use and if psychiatric treatment prior
to admission influenced BZD prescribing one year after
admission. Finally, we assessed both the proportion of the
different types of BZDs prescribed and the very long-term
BZD prescription rates after admission into treatment.
Methods
Study population
This study included 33203 patients aged between 18 and
67 years old who were consecutively admitted for public
outpatient treatment for DUD between January 1, 2000
and December 31, 2010 (Fig. 1).
Data sources
This study was based on data from the Danish Substance
Abuse Treatment Register (DSATR) [26], the Danish
National Prescription Database (DNPR) [27], and the
Danish Psychiatric Central Research Register (PCRR) [28].
Data was obtained for the period of January 1, 1999 to
December 31, 2011. All data sources were linked by use
of the personal identification number, a unique identi-
fier assigned to all Danish residents since 1968 [29].
The DSATR was used to identify patients in treatment
for different DUDs. The register was established in 1996
and contains information on all patients receiving treat-
ment in publically funded outpatient drug treatment fa-
cilities in Denmark. All treatment in these facilities is
provided free of charge to the patient, as Denmark pro-
vides access to universal health care (including DUD
treatment) for all residents. There are few privately funded
drug treatment facilities, except for treatment of alcohol
use disorders. Therefore practically all patients in treat-
ment for DUDs are included in this study. The date of
admission into treatment was registered. Patients are
registered with one self-reported primary drug of abuse
used upon admission into treatment, where patients are
asked about “primary drug” in relation to treatment
needs. Besides illicit non-prescription drugs, prescription
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drugs such as methadone, buprenorphine, and BZDs
could also be reported as their “primary drug” of abuse.
The DNPR contains information on all individual
prescription drugs dispensed through pharmacies in
Denmark since 1994 to patients outside of institutions
such as hospitals and drug treatment facilities. Informa-
tion about all prescriptions from ambulatory care,
whether publicly reimbursed or not, is stored in the
DNPR. Drugs are classified according to the Anatomical
Therapeutic Chemical (ATC) classification [30]. The study
used prescription data about BZDs, opioid analgesics, opi-
oid maintenance medication (methadone, buprenorphine),
and Z-hypnotics from the DNPR, which cover all pa-
tient prescriptions in Denmark. The data collected for
this study included; patient unique identifying number
(encrypted), gender, the date the medication was dispensed,
and medication information [brand name, ATC-code, and
defined daily dose (DDD)].
Benzodiazepines were defined by the ATC-code N05BA,
N05CD, and N03AE01 in the ATC-classification system.
Opioid analgesics were defined by the ATC-code N02A.
Methadone and buprenorphine prescribed for opioid
maintenance treatment were defined by the ATC-code
N07BC02 and N07BC01/N07BC51, respectively. Z-hypnotics
were defined by the ATC-code N05CF. Methadone and
buprenorphine are used for both opioid maintenance
treatment and pain treatment in Denmark. The present
study included prescriptions of methadone and bupre-
norphine when these medications were prescribed for
either indication. In this paper the terms ‘prescribed
drug’ and ‘used drug’ are used interchangeably to describe
dispensed drugs at pharmacies. For each prescription, the
numbers of DDD dispensed were recorded. A DDD is de-
fined as the assumed average maintenance dose per day
for a medication used for its main indication in adults
(Table 1) [30, 31].
Information about psychiatric diagnosis was obtained
from the PCRR. The PCRR contains data on all psychi-
atric hospitalizations in Denmark since 1970, psychiatric
ambulatory visits and emergency department contacts
Fig. 1 Flow chart indicating the procedure for generating the study population
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since 1995. Discharge/contact diagnoses from the PCRR
are coded according to ICD-10. A patient was only iden-
tified as having received psychiatric treatment if a diag-
nosis with the ICD-10 code F01-F99 was given during
treatment. For certain analyses, these ICD-10 codes were
further grouped into seven categories.
Analysis strategy
Study entry was set as the date of first admission into
treatment for DUD during the study entry period, 2000–
2010. We followed patients during the first year (365 days)
after admission with respect to BZD prescription. Patients
in the upper quartile received a yearly BZD dose of ≥584
DDD. The patients were categorized into two groups by
amount prescribed during the first year after admission:
(i) yearly dose <584 DDD (moderate-high dose) and (ii)
yearly dose ≥584 DDD (very high dose). First, we com-
pared characteristics at the time of admission between
groups with and without a prescription for BZDs in
moderate-high and very high doses. Further, for these
groups we investigated the proportion of patients with a
prescription for other potentially addictive drugs and psy-
chiatric diagnoses. We assessed the proportion (%) with
95 % confidence intervals (CI) of different categories of
psychiatric diagnoses that were given to patients with and
without a prescription for BZDs in moderate-high and
very high doses during the first year after admission.
Second, a prescription of BZDs during the year prior
to admission into treatment may likely influence the
prescription pattern after admission. Therefore we per-
formed the following analyses in two different strata. In
the first strata, we included patients with at least one
prescription of BZDs in the year prior to admission
(previous users). In the second strata, we included patients
who had not received a BZD prescription in the year prior
to admission, but who had at least one prescription of
BZDs in the year after admission (new users). Variables
potentially associated with prescription of BZDs in
moderate-high and very high doses were estimated by
multinomial logistic regression for both strata.
Third, we assessed the proportion of different types of
BZDs in the moderate-high and the very high dose
categories for both previous and new users. Finally, we
investigated very long-term prescription of BZDs for
previous and new users in 2000–2007 (N = 5374 and
N = 2122, respectively). For this analysis, patients were
consecutively excluded if they had died during the year
of assessment (total; n = 510 and n = 120, respectively).
A very long-term prescription of BZDs was defined as
having had at least one prescription of BZDs in at least
four consecutive years after the admission date, and in-
cluded long-term sporadic use. We calculated the me-
dian and interquartile range (IQR 25 to 75 %) of DDDs
of BZDs in the fourth year for each group.
Statistical analysis
All analyses were conducted using SPSS version 19.0 for
Windows. To test for differences between groups, Chi-
square analysis and t-test were used. Unadjusted and ad-
justed relative risk ratio (RRR and aRRR) with 95 % CI
was estimated by multinomial regression analysis. In
multinomial regression analysis, gender, age group at
study entry date, primary drug use, and psychiatric diag-
nosis within 1 year prior to study entry were included in
the model as independent variables. The level of signifi-
cance was set to P < 0.05.
Table 1 ATC code and Defined Daily Dose (DDD) of prescribed benzodiazepinesa
ATC code 1 DDD (oral administration) 584 DDD (oral administration)
Alprazolam N05BA12 1 mg 584 mg
Bromazepam N05BA08 10 mg 5840 mg
Chlordiazepoxide N05BA02 30 mg 17520 mg
Clobazam N05BA09 20 mg 11680 mg
Clonazepam N03AE01 8 mg 4672 mg
Diazepam N05BA01 10 mg 5840 mg
Estazolam N05CD04 3 mg 1752 mg
Flunitrazepam N05CD03 1 mg 584 mg
Flurazepam N05CD01 30 mg 17520 mg
Lorazepam N05BA06 2.5 mg 1460 mg
Midazolam N05CD08 15 mg 8760 mg
Nitrazepam N05CD02 5 mg 2920 mg
Oxazepam N05BA04 50 mg 29200 mg
Triazolam N05CD05 0.25 mg 146 mg
Abbreviations: ATC, Anatomical Therapeutic Chemical
aIntake of 1 DDD daily of benzodiazepines in a 1 year period results in a total intake of 365 DDD
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Ethics
The Danish Data Protection Agency has approved all pro-
cedures in relation to data collection from all used da-
tabases, and also storage of the data. The National
Committee on Health Research Ethics in Denmark was
informed about the study and determined that the
study did not need to be reported to the Committee.
All linkages were performed within Statistics Denmark,
a governmental institution that collects and maintains
electronic records for a broad spectrum of statistical
and scientific purposes.
Results
A total of 33203 patients between the ages of 18 to
67 years were admitted for outpatient treatment for
DUDs during January 1, 2000 until December 31, 2010.
The mean age was 31 years (SD ± 11) at first admission,
and 8177 (24.6 %) were female. During the first year
after admission 8705 patients (26.2 %) were prescribed
BZDs. The yearly mean dose prescribed was 438.1 DDD
during the first year after admission, and the median
was 175.0 DDD (interquartile range, 40.0 to 584.5). Of
the patients with a BZD prescription, 3086 (35.5 %) were
prescribed BZDs in a yearly dose higher than 365 DDD
during the year after admission.
Table 2 compares characteristics in the groups with
and without a BZD prescription in the different dosage
categories at the time of admission. Age at admission
was highest in the group with the highest amounts of
prescribed BZDs (mean 41.0 years). The proportion of
females was higher in groups with a BZD prescription
compared to the group without a BZD prescription. Pa-
tients with opioids reported as their primary drug used
were overrepresented in the group with the highest
amounts of prescribed BZDs (Table 2). The proportion
of patients with opioids as their primary drug used was
53.6 % in this group compared to 40.4 % in the group
with the lowest amounts of BZDs, and 20.4 % in the
group without a BZD prescription. Conversely, the pa-
tients with cannabis or central stimulating drugs re-
ported as their primary drug used were overrepresented
in the group without a prescription for BZDs. During
the year prior to admission the proportion of patients
receiving psychiatric treatment was lowest for the group
without BZD prescription (16.9 %) and highest in the
group with the lowest amounts of BZDs (27.3 %).
Among patients without a BZD prescription during the
Table 2 Characteristics of patients at the time of admission into treatment for DUDs, by prescription and dose category of
benzodiazepines
No prescription of
benzodiazepines
1 year after admission
Prescription of benzodiazepines
1 year after admission in moderate-
high doses <584 DDDa
Prescription of benzodiazepines
1 year after admission in very
high doses ≥584 DDDa
p value
N (%) N (%) N (%)
Number of individuals 24498 6528 2177
Age in years at admission date, mean (SD) 29.2 ± 9.7 35.3 ± 10.7 41.0 ± 9.5 <0.001
Gender <0.001
Male 18884 77.1 4630 70.9 1512 69.5
Female 5614 22.9 1898 29.1 665 30.5
Primary drug use at admission <0.001
Cannabis 9212 37.6 1193 18.3 84 3.9
Opioids 5011 20.4 2639 40.4 1166 53.6
Methadone or buprenorphine 1236 5.0 955 14.6 594 27.3
Heroin 3454 14.1 1458 22.3 463 21.3
Other opioids 321 1.3 226 3.5 109 5.0
Benzodiazepines 213 0.9 207 3.2 83 3.8
Central stimulating drugsb 3648 14.9 534 8.2 50 2.3
Other illicit drugs/unknown 6414 26.2 1955 29.9 794 36.5
Psychiatric treatment received in 1 year
prior to admissionc
4148 16.9 1782 27.3 430 19.8 <0.001
Prescription of benzodiazepines 1 year
prior to admission
2464 10.1 4113 63.0 2026 93.1 <0.001
Abbreviations: DUDs, drug use disorders; DDD, Defined Daily Dose
aIntake of 1 DDD daily of benzodiazepines in a 1 year period results in a total intake of 365 DDD
bAmphetamine, cocaine, and MDMA
cInformation obtained from the Danish Psychiatric Central Research Register
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year after admission into treatment, 10.1 % were pre-
scribed BZDs in the year prior to admission. However,
in the groups with a prescription of BZDs after admis-
sion in lower and higher amounts, 63.0 % and 93.1 %
respectively, were prescribed BZDs in the year prior to
admission (Table 2).
During the year after admission, the proportion of
patients with a prescription of potentially addictive
drugs (opioid analgesics, opioid maintenance medication,
and Z-hypnotics) was highest in the group with the high-
est amounts of BZDs and lowest in the group without a
BZD prescription (Table 3).
During the year after admission, only the psychiatric
diagnosis “mental and behavioral disorders due to psycho-
active substance use” was more common in the groups
with prescription of BZDs compared to the group without
prescription of BZDs (Table 4).
From 2000 to 2010, the proportion of previous and
new users with a BZD prescription during the first year
after admission reduced continuously from 71.4 % and
18.1 % to 62.2 % and 5.9 %, respectively (data not shown).
With respect to factors associated with having a BZD
prescription during the year after admission, the analyses
were performed stratified according to the BZD prescrip-
tion prior to admission (Tables 5 and 6). In both strata, no
association after adjustment was observed between female
gender and the prescription of very high amounts of
BZDs. In the strata with new users of BZDs, females
were more likely than males to be prescribed BZDs in
moderate-high amounts (aRRR = 1.2, 95 % CI 1.1-1.3).
Differences between strata in the association between
age and BZD prescription in moderate-high and very high
amounts were observed. In the strata with previous users
of BZDs (Table 5), the RRR increased with increasing age
in both dose categories (oldest age group: aRRR = 3.3,
2.7-3.9; aRRR = 7.8, 6.2-9.9). However in the strata with
new users of BZDs, the RRR was increased only in
older age groups among patients with prescription of
BZDs in moderate-high amounts (aRRR = 3.3, 2.7-3.9).
Patients with opioids (methadone and buprenorphine;
heroin) reported as their primary drug used were more
likely to be prescribed BZDs in moderate-high and particu-
larly very high doses, as compared to cannabis as their pri-
mary drug used in the strata of new BZD users (very high
dose: aRRR (methadone and buprenorphine) = 45.7, 95 %
CI 20.9-99.9; aRRR (heroin) = 17.1, 8.0-36.5) (Table 6). A
similar but less strong association was observed in the
strata of previous BZD users. Receiving psychiatric treat-
ment prior to admission reduced the risk of being pre-
scribed BZDs in very high doses in both strata (however,
not significant for new users).
For both previous and new BZD users, the proportion
of patients with prescription of more than one type of
BZD was lowest for patients with prescription of BZDs
in the lowest doses (29.2 %; 18.6 %) and highest for pa-
tients with prescription of BZDs in the highest doses
(62.0 %; 66.9 %) (Table 7). Diazepam was the most
commonly prescribed type of BZD to previous users
(34.8 %), whilst oxazepam was the most common type
prescribed to new users (28.6 %). However, among both
of these groups with prescription of BZDs in only very
high doses, nitrazepam was the most commonly pre-
scribed type (53.7 %; 72.8 %).
A high proportion of patients with previous prescrip-
tion of BZDs continued into very long-term use of pre-
scribed BZDs after admission (4 years after admission:
62.6 %) (Fig. 2). Even in the group of patients without
previous prescription of BZDs, 27.5 % continued into
very long-term use. During the first year of prescription,
the median and interquartile range of DDD was 343.9
(IQR 83.3 to 797.0); 50.0 (18.0 to 166.7) for previous and
new users of BZDs, respectively. During the fourth year
Table 3 Prescription of other addictive drugs and psychiatric treatment for patients in the first year after admission into treatment
for DUDs
No prescription of
benzodiazepines
1 year after admission
Prescription of benzodiazepines
1 year after admission in moderate-
high doses <584 DDDa
Prescription of benzodiazepines
1 year after admission in very
high doses ≥584 DDDa
p value
N (%) N (%) N (%)
Number of individuals 24498 6528 2177
Prescription of other drugs 1 year
after admission
Opioid analgesics 1677 6.9 1323 20.3 668 30.7 <0.001
Opioid maintenance medication
(methadone, buprenorphine)
2903 11.9 2271 34.8 1238 56.9 <0.001
Z-hypnotics 1489 6.1 1444 22.1 334 15.3 <0.001
Psychiatric treatment received
in 1 year after admissionb
3791 15.5 1825 28.0 431 19.8 <0.001
Abbreviations: DUDs, drug use disorders; DDD, Defined Daily Dose
aIntake of 1 DDD daily of benzodiazepines in a 1 year period results in a total intake of 365 DDD
bInformation obtained from the Danish Psychiatric Central Research Register
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of prescription, the median and interquartile range of
DDD was 405.0 (IQR 122.0 to 937.5); 118.8 (30.0 to
416.8) for previous and new users of BZDs, respectively.
Discussion
In this large nationwide study involving 33203 Danish
patients admitted during an 11-year period to outpatient
treatment for all types of DUDs, one out of four received
at least one BZD prescription during the first year after
admission. Of these, 29 % were new users of prescribed
BZDs. Among patients with an opioid as their primary
drug used, 43 % were prescribed BZDs during the first
year after admission, which was three times higher than
for patients with cannabis or central stimulating drugs
as their primary drug used. Diazepam was the most
commonly prescribed type of BZD. Collectively, the find-
ings point toward a prescribing practice of BZDs that
overall does not follow clinical guidelines, and indicate an
inappropriate prescription of benzodiazepines in many
cases more than treatment for psychiatric disorders.
Our findings are consistent with the results of other
studies showing that having a DUD increases the risk of
BZD use [32]. Particularly, a high prevalence of BZD use
among patients in treatment for opioid use disorder cor-
responds to the findings reported elsewhere [9, 33]. Use
of BZDs in high doses was observed among patients
with an OMT medication, methadone or buprenorphine,
as primary drug used. This finding is consistent with the
results of studies showing that users of OMT medication
were prescribed higher doses of BZDs as compared to
users of heroin [14].
Compared to the general population in the same age
group and same time period in Denmark (one year
prevalence 5-6 %) [23], the prevalence of BZD use was
five times higher among patients with all types of DUD,
and eight times higher among patients with opioids as
their primary drug used. Although a decreasing trend in
use of BZDs was observed in our study, the prevalence
of BZD use in 2010 was approximately four times higher
among patients with all types of DUD as compared to
the general population. This excess BZD use among pa-
tients with DUD may therefore be of continued rele-
vance after the study period.
In contrast to the general population, where female
gender predicts BZD use, our study indicates that overall
there was no association between gender and use of BZDs
[34]. However, in consistency with the general population,
use of BZDs was overall more common in older age
groups compared with younger [25, 35].
Many of the patients admitted for DUD treatment re-
quire treatment for their harmful use of non-prescribed
BZDs [36, 37]. The cessation of such non-prescribed
BZDs is complex and often requires medical support,
which can include the prescribing and tapering of BZDs
[38]. In our study, more than one quarter of all users
of BZDs were new users. Of these, one out of four
Table 4 Psychiatric diagnoses (ICD-10 code: F00-F99) given to patients in psychiatric treatment in the first year after admission into
treatment for DUDsa
No prescription of
benzodiazepines
1 year after admission
Prescription of benzodiazepines
1 year after admission in moderate-
high doses <584 DDDb
Prescription of benzodiazepines
1 year after admission in very
high doses ≥584 DDDb
N = 3791 N = 1825 N = 431
N % (95 % CI) N % (95 % CI) N % (95 % CI)
Mental and behavioural disorders due to psychoactive
substance use (ICD-10 code: F10–F19)
1821 48.0 (46.4-49.6) 1127 61.8 (59.5-64.0) 259 60.1 (55.3-64.7)
Schizophrenia and related disorders (ICD-10 code:
F20–F29)
362 9.5 (8.6-10.5) 226 12.4 (10.9-14.0) 47 10.9 (8.2-14.3)
Mood disorders (ICD-10 code: F30–F39) 473 12.5 (11.5-13.6) 217 11.9 (10.5-13.5) 31 7.2 (5.0-10.2)
Neurotic, stress-related, and somatoform disorders
(ICD-10 code: F40–F48)
629 16.6 (15.4-17.8) 296 16.2 (14.6-18.0) 63 14.6 (11.5-18.4)
Disorders of adult personality and behaviour
(ICD-10 code: F60–F69)
390 10.3 (9.4-11.3) 194 10.6 (9.3-12.2) 32 7.4 (5.2-10.4)
Behavioural and emotional disorders with onset in
childhood (ICD-10 code: F90–F98)
266 7.0 (6.2-7.9) 53 2.9 (2.2-3.8) 4 0.9 (0.3-2.5)
Other mental disorders (ICD-10 code: F00–F09,
F50–F59, F70–F89, F99)c
253 6.7 (5.9-7.5) 104 5.7 (4.7-6.9) 26 6.0 (4.1-8.8)
Totald 4194 2253 462
Abbreviations: DUDs, drug use disorders; DDD, Defined Daily Dose
aInformation obtained from the Danish Psychiatric Central Research Register
bIntake of 1 DDD daily of benzodiazepines in a 1 year period results in a total intake of 365 DDD
cF00–F09: Organic, including symptomatic, mental disorders; F50–F59: Behavioural syndromes associated with physiological disturbances and physical factors;
F70–79: Mental retardation; F80–89: Disorders of psychological development; F99: Unspecified mental disorder
dIt is possible for one patient to be given more than one type of psychiatric diagnosis
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continued with a very long-term prescription. If a pre-
scription of BZDs is initiated, it should normally not
exceed four weeks, or a tapering down period should
be agreed upon with the patient prior to treatment to
avoid a long-term prescription [22]. For high-risk drug
users and particularly opioid users, a short tapering
down period with frequent medication pickup should
be considered [39].
The amount of BZDs prescribed in this study was
measured by use of DDD (Defined Daily Dose). The
therapeutic amount of BZD for its main indication is de-
fined as 1 DDD per day, equivalent to 365 DDD per year
[30]. In our study, one-third were prescribed above 365
DDD per year, which indicates inappropriate use of BZD.
Prescription of BZDs in high doses should in general be
avoided, particularly for patients with DUD due to the
high risk for abuse. Involvement of specialized psychiatric
care might reduce the prescribing of BZDs in high doses
by offering a psychiatric diagnostics that could inform an
alternative and more effective therapeutic offer [40]. Our
results support this as receiving psychiatric treatment
prior to admission seemed to reduce the risk of being pre-
scribed BZDs in very high doses.
Each type of BZD possess different effects, and their
appeal to drug users differ accordingly [17]. In our study,
diazepam was the most commonly prescribed type of
BZD. This prescribing practice may be less than optimal,
as diazepam has been reported as attractive among drug
users given its fast onset and superior euphoriant effect
compared to other types [17, 41, 42]. In addition to di-
azepam, other types of BZDs were prescribed, and one-
third were prescribed more than one type of BZD. Use
of more than one BZD at a time may indicate inappro-
priate use of BZDs [43]. This is supported by our find-
ings as the majority of patients receiving BZDs in very
high doses were prescribed more than one type of BZD.
The strengths of this study were that it covers all pa-
tients admitted to treatment for all types of DUD in a
nationwide study. The unique personal identity number
provides high quality linkages between the population-
based registries on DUD treatment, prescriptions, and
psychiatric treatment in Denmark. There were no miss-
ing outcome variables of prescribed medications due to
complete registry linkage.
The limitations of this study were that medications
dispensed at hospitals and other institutions, sometimes
Table 5 Relative risk ratio (RRR) from multinomial logistic regression of having a continued prescription of benzodiazepines according to
different factors
Prescription of benzodiazepines 1 year after admission
in moderate-high doses <584 DDDa
Prescription of benzodiazepines 1 year after admission
in very high doses ≥584 DDDa
Unadjusted RRR Adjustedb RRR
(95 % CI)
p value Unadjusted RRR Adjustedb RRR
(95 % CI)
p value
Female 1.1 1.0 (0.9-1.2) 0.310 1.2 1.0 (0.9-1.2) 0.639
Age group at admission date
18 – 27 years 1.0 (referent) 1.0 (referent) 1.0 (referent) 1.0 (referent)
28 – 37 years 1.8 1.7 (1.4-1.9) <0.001 3.8 2.8 (2.3-3.5) <0.001
38 – 47 years 2.4 2.1 (1.8-2.4) <0.001 7.6 4.9 (4.0-6.1) <0.001
48 – 67 years 3.7 3.3 (2.7-3.9) <0.001 13.3 7.8 (6.2-9.9) <0.001
Primary drug use at admission
Cannabis 1.0 (referent) 1.0 (referent) 1.0 (referent) 1.0 (referent)
Methadone or buprenorphine 2.4 1.8 (1.5-2.2) <0.001 15.2 8.3 (6.2-11.1) <0.001
Heroin 1.5 1.3 (1.1-1.6) 0.001 5.1 3.6 (2.7-4.8) <0.001
Other opioids 2.0 1.5 (1.1-2.1) 0.005 9.1 5.2 (3.6-7.7) <0.001
Benzodiazepines 2.5 2.1 (1.5-2.8) <0.001 9.4 6.9 (4.5-10.6) <0.001
Central stimulating drugsc 0.9 0.9 (0.7-1.1) 0.431 1.1 1.1 (0.7-1.7) 0.633
Other illicit drugs/unknown 1.7 1.4 (1.2-1.6) <0.001 7.6 4.6 (3.5-6.0) <0.001
Psychiatric treatment received
in 1 year prior to admissiond
1.0 1.2 (1.0-1.3) 0.006 0.6 0.6 (0.5-0.7) <0.001
Group of previous users without prescription of benzodiazepines, n = 2464; group of previous users with prescription of benzodiazepines in moderate-high doses,
n = 4113; group of previous users with prescription of benzodiazepines in very high doses, n = 2026.
Abbreviations: DDD, Defined Daily Dose; CI, confidence interval.
aIntake of 1 DDD daily of benzodiazepines in a 1 year period results in a total intake of 365 DDD.
bAdjusted for gender, age group at admission date, primary drug use at admission, and psychiatric treatment received in 1 year prior to admission.
cAmphetamine, cocaine, and MDMA.
dInformation obtained from the Danish Psychiatric Central Research Register.
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Table 6 Relative risk ratio (RRR) from multinomial logistic regression of having a new prescription of benzodiazepines according to
different factors
Prescription of benzodiazepines 1 year after admission
in moderate-high doses <584 DDDa
Prescription of benzodiazepines 1 year after admission
in very high doses ≥584 DDDa
Unadjusted RRR Adjustedb RRR
(95 % CI)
p value Unadjusted RRR Adjustedb RRR
(95 % CI)
p value
Female 1.2 1.2 (1.1-1.3) <0.001 0.8 0.8 (0.5-1.2) 0.818
Age group at admission date
18 – 27 years 1.0 (referent) 1.0 (referent) 1.0 (referent) 1.0 (referent)
28 – 37 years 1.7 1.4 (1.2-1.5) <0.001 4.1 1.9 (1.3-2.9) 0.003
38 – 47 years 1.9 1.3 (1.2-1.5) <0.001 3.8 1.2 (0.7-2.0) 0.488
48 – 67 years 1.9 1.3 (1.1-1.5) 0.006 4.0 1.1 (0.6-2.2) 0.710
Primary drug use at admission
Cannabis 1.0 (referent) 1.0 (referent) 1.0 (referent) 1.0 (referent)
Methadone or buprenorphine 4.2 3.8 (3.2-4.4) <0.001 52.9 45.7 (20.9-99.9) <0.001
Heroin 2.7 2.5 (2.2-2.9) <0.001 20.3 17.1 (8.0-36.5) <0.001
Other opioids 2.8 2.4 (1.7-3.3) <0.001 22.5 20.3 (6.5-63.7) <0.001
Benzodiazepines 4.2 3.8 (2.7-5.4) <0.001 14.2 15.1 (3.2-71.7) 0.001
Central stimulating drugsc 1.1 1.0 (0.9-1.2) 0.572 1.9 1.9 (0.7-5.6) 0.224
Other illicit drugs/unknown 1.5 1.4 (1.3-1.7) <0.001 5.3 5.2 (2.3-11.4) <0.001
Psychiatric treatment received in
1 year prior to admissiond
1.4 1.5 (1.4-1.7) <0.001 0.5 0.7 (0.4-1.3) 0.320
Group without prescription of benzodiazepines, n = 22034; group of new users with prescription of benzodiazepines in moderate-high doses, n = 2415; group of
new users with prescription of benzodiazepines in very high doses, n = 151
Abbreviations: DDD, Defined Daily Dose; CI, confidence interval
aIntake of 1 DDD daily of benzodiazepines in a 1 year period results in a total intake of 365 DDD
bAdjusted for gender, age group at admission date, primary drug use at admission, and psychiatric treatment received in 1 year prior to admission
cAmphetamine, cocaine, and MDMA
dInformation obtained from the Danish Psychiatric Central Research Register
Table 7 Types of benzodiazepines prescribed to previous and new users in the first year after admission for treatment for DUDs
Prescription of benzodiazepines to previous users in the first year
after admission
Prescription of benzodiazepines to new users in the first year
after admission
Moderate-high doses <584 DDDa
N = 4113
Very high doses ≥584 DDDa
N = 2026
Moderate-high doses <584 DDDa
N = 2415
Very high doses ≥584 DDDa
N = 151
Benzodiazepine
type
N % N % N % N %
Alprazolam 398 9.7 287 14.2 200 8.2 32 21.2
Bromazepam 303 7.4 450 22.2 101 4.2 30 19.9
Chlordiazepoxide 692 16.8 189 9.3 624 25.8 20 13.2
Clonazapam 739 18.0 252 12.4 305 12.6 14 9.3
Diazepam 1224 29.8 914 45.1 484 20.0 50 33.1
Flunitrazepam 82 2.0 201 9.9 46 1.9 18 11.9
Nitrazepam 756 18.4 1087 53.7 393 16.3 110 72.8
Oxazepam 1284 31.2 329 16.2 692 28.7 43 28.5
Other 186 4.5 188 9.3 104 4.3 13 8.6
Totalb 5664 137.7 3897 192.3 2949 122.1 330 218.5
Multiple 1202 29.2 1257 62.0 449 18.6 101 66.9
Abbreviations: DUDs, drug use disorders; DDD, Defined Daily Dose
aIntake of 1 DDD daily of benzodiazepines in a 1 year period results in a total intake of 365 DDD
bIt is possible for one patient to be prescribed more than one type of benzodiazepine
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without individual prescriptions, are not registered at an
individual level and hence are not included in this study.
Benzodiazepines prescribed from drug treatment facil-
ities to alleviate alcohol withdrawal symptoms are overall
not included in the study, as BZDs prescribed with such
an indication most often are dispensed from the treat-
ment facility and not registered in the Danish National
Prescription Database. Further, dispensed medications
from pharmacies are not necessarily consumed by the
recipients, and this study cannot account for persons
who may have given away or sold their prescribed medi-
cations. If the type of BZD prescribed to one patient
consecutively changed during a year it may have been
registered as being prescription of multiple types of
BZD. However, a high proportion of patients with pre-
scription of multiple types of BZDs were receiving very
high doses which could indicate use of more than one type
at a time. Only OMT (opioid maintenance treatment)
medication dispensed from a pharmacy was included in
this study, as OMT medication dispensed from a drug
treatment facility is not registered in the Danish National
Prescription Database. Psychiatric diagnoses exclu-
sively from general practitioners, drug treatment facil-
ities, or somatic hospitals are not in registered the
Danish Psychiatric Central Research Register and there-
fore not included in this study. Further, patients may have
used a combination of drugs where choice of one primary
drug use can be difficult and lead to misclassification.
Conclusions
The studied population in this nationwide sample in-
cluded all patients with a DUD. In that view, regardless of
the primary drug used, patients had too high prescription
rates of BZDs, and this particularly applied to patients
with an opioid use disorder. Our findings therefore have
relevance for all physicians involved in DUD treatment.
Given that BZDs only have a very narrow indication as
psychiatric treatment for this patient group, the current
treatment as presented in this study seems less than op-
timal. This is underlined by the finding that admitting
into treatment for DUDs with prescribed BZDs did not
seem to increase specialized psychiatric care involve-
ment. No difference regarding the prevalence of anxiety
disorders have been reported among patients with differ-
ent types of DUDs [12]. Still, the proportion of BZD
users was three times higher among patients treated for
opioid use when compared to patients treated for use of
cannabis or central stimulating drugs. Opioids combined
with BZDs are known to induce a greater level of eu-
phoria, as opposed to cannabis and central stimulating
drugs. Further, inappropriate prescription patterns of BZD
were identified in this study with prescription of multiple
and non-optimal types, high doses, very long-term pre-
scription, and co-prescription of other potentially ad-
dictive drugs.
Overall, BZDs were prescribed to DUD patients in a
fashion that in many cases indicated inappropriate pre-
scribing to patients more than treatment for psychiatric
disorders. This finding might reflect a liberal prescribing
practice among physicians at drug treatment facilities in
Denmark, which has previously been described regarding
other addictive medications [44, 45]. Further, it empha-
sizes the potential risk of harm when BZD prescribing
practices do not follow clinical guidelines. Our results
reinforce the need for health systems to promote the use
of prescription drug monitoring programs to identify in-
appropriate BZD prescribing patterns among patients, and
help physicians link such patients to more appropriate
care. Patients with patterns of inappropriate BZD use
deserve medical support while tapering off their BZD
dependence. DUD patients with comorbid psychiatric
disorders in need of long-term BZD prescription are likely
a minority, and co-management of specialized psychiatric
care should be considered part of an appropriate BZD
treatment for this patient group. For the remainder of the
patients, physicians would likely benefit their patients if
Fig. 2 Proportion of patients (%) with very long-term prescription of benzodiazepines after admission for treatment for drug use disorders
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BZDs are avoided rather than prescribed; however to hold
the restrictive role is more of a challenge than to be a
liberal prescriber.
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